Idera Pharmaceuticals Inc (NASDAQ:IDRA) to Present at JMP Securities LLC Healthcare Focus Conference October 6

Idera Pharmaceuticals, Inc (NASDAQ:IDRA) will speak at the JMP Securities LLC Healthcare Focus Conference on Monday, September 6 at 9:00 am ET.  A webcast of the presentation will be available at ir.iderapharma.com.

Idera Pharmaceuticals, Inc. (Idera) is a biotechnology company engaged in the discovery and development of synthetic deoxyribonucleic acid (DNA)-and ribonucleic acid (RNA)-based drug candidates targeted to Toll-Like Receptors (TLRs), to treat infectious diseases, autoimmune diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. TLRs are specific receptors present in immune system cells that recognize the DNA or RNA of pathogens, such as bacteria or viruses and initiate an immune response.

IMO-2125, a TLR9 agonist, is the Company lead drug candidate for infectious diseases. As of December 31, 2007, Idera conducted a Phase I clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection who have not responded to current standard of care therapy. As part of the Company’s infectious disease program, it is also evaluating RNA-based compounds that act as agonists of TLR7 and TLR8.

Read more Business News on The Global Market Directory.

About The Global Market Directory (TheGMD)

TheGMD provides an online global directory listing featuring public companies, stock brokers, brokerage firms and individuals.  The GMD provides profiles for Brokerage Firms, Stock Brokers and Individuals in addition to Public Companies.

The GMD is a division of TransWorldNews, Inc. Companies can utilize the TransWorldNews press release distribution services and have all news releases attached to their GMD profile.

Create your profile on The Global Market Directory.